Pazopanib

From Wikipedia, the free encyclopedia - View original article

Pazopanib
Pazopanib.svg
Pazopanib3Dan.gif
Systematic (IUPAC) name
5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
Clinical data
Trade namesVotrient
AHFS/Drugs.commonograph
MedlinePlusa610013
Licence dataEMA:LinkUS FDA:link
Pregnancy cat.D (AU) D (US)
Legal statusPrescription Only (S4) (AU) -only (CA) POM (UK) -only (US)
RoutesOral
Pharmacokinetic data
Protein binding>99%[1]
MetabolismHepatic (CYP3A4, 1A2 and 2C8-mediated)[1]
Half-life31.9 hours[1]
ExcretionFaeces (primary), urine (<4%)[1]
Identifiers
CAS number444731-52-6 N
ATC codeL01XE11
PubChemCID 11525740
ChemSpider9700526 YesY
UNII7RN5DR86CK YesY
ChEMBLCHEMBL477772 N
Chemical data
FormulaC21H23N7O2S 
Mol. mass437.517 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Pazopanib
Pazopanib.svg
Pazopanib3Dan.gif
Systematic (IUPAC) name
5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
Clinical data
Trade namesVotrient
AHFS/Drugs.commonograph
MedlinePlusa610013
Licence dataEMA:LinkUS FDA:link
Pregnancy cat.D (AU) D (US)
Legal statusPrescription Only (S4) (AU) -only (CA) POM (UK) -only (US)
RoutesOral
Pharmacokinetic data
Protein binding>99%[1]
MetabolismHepatic (CYP3A4, 1A2 and 2C8-mediated)[1]
Half-life31.9 hours[1]
ExcretionFaeces (primary), urine (<4%)[1]
Identifiers
CAS number444731-52-6 N
ATC codeL01XE11
PubChemCID 11525740
ChemSpider9700526 YesY
UNII7RN5DR86CK YesY
ChEMBLCHEMBL477772 N
Chemical data
FormulaC21H23N7O2S 
Mol. mass437.517 g/mol
 N (what is this?)  (verify)

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.[2][3][4][5]

Medical uses[edit]

It is approved by numerous regulatory administrations worldwide (including the FDA (19 October 2009), EMA (14 June 2010), MHRA (14 June 2010) and TGA (30 June 2010)) for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas.[1][2][3][4][5] In Australia it is subsidised under the PBS, under a number of conditions, including:[6]

It has also demonstrated therapeutic properties in patients with ovarian and non-small cell lung cancer.[7]

Adverse effects[edit]

Adverse effects by frequency:[1][2][3][4][5][8]

Very common (>10% frequency):

Common (1-10% frequency):

Uncommon (0.1-1% frequency):

Rare (<0.1% frequency):

Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma. Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.

Notes

  1. ^ Usually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment
  2. ^ This includes leucopenia, thrombocytopenia and neutropenia
  3. ^ This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia


Summary
The most common side effects of pazopanib are nausea, vomiting, diarrhoea (occurs in about half of patients), changes in hair colour, hypertension (which usually occurs during the first few weeks of treatment), appetite loss, hyperglycaemia, hypoglycaemia, electrolyte abnormalities (including hypocalcaemia, hypomagnesemia, hypophosphatemia), lab anomalies (including increased AST, ALT and protein in the urine), oedema, hair loss or discolouration, taste changes, abdominal pain, hypertension, rash, fatigue and myelosuppression (including leucopenia, neutropenia, thrombocytopenia and lymphopenia).[9] It has been associated with a low, but real risk of potentially fatal liver damage.[9]

Contraindications[edit]

The only contraindication is hypersensitivity to pazopanib or any of its excipients.[4] Cautions include:[1]

It has one black box warning by the US FDA, severe hepatotoxicity, including fatalities.[1]

Interactions[edit]

Drug interactions include:[1]

Overdose[edit]

The treatment for overdose is purely supportive and the symptoms include grade 3 hypertension and fatigue.[4]

Mechanism of action[edit]

It is a multikinase inhibitor, with c-KIT, FGFR, PDGFR and VEGFR being amongst the inhibited enzymes.[1][9][10][11][12]

References[edit]

  1. ^ a b c d e f g h i j "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014. 
  2. ^ a b c "VOTRIENT (pazopanib hydrochloride) tablet, film coated [GlaxoSmithKline LLC]" (PDF). DailyMed. GlaxoSmithKline LLC. November 2013. Retrieved 27 January 2014. 
  3. ^ a b c "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Retrieved 27 January 2014. 
  4. ^ a b c d e "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014. 
  5. ^ a b c "PRODUCT INFORMATION VOTRIENT® TABLETS" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014. 
  6. ^ "Pharmaceutical Benefits Scheme (PBS) - Pazopanib". Pharmaceutical Benefits Scheme. Australian Government. Retrieved 27 January 2014. 
  7. ^ "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10. 
  8. ^ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.  edit
  9. ^ a b c Zivi, A; Cerbone, L; Recine, F; Sternberg, CN (September 2012). "Safety and tolerability of pazopanib in the treatment of renal cell carcinoma". Expert Opinion on Drug Safety 11 (5): 851–859. doi:10.1517/14740338.2012.712108. PMID 22861374. 
  10. ^ Verweij, J; Sleijfer, S (May 2013). "Pazopanib, a new therapy for metastatic soft tissue sarcoma". Expert Opinion on Pharmacotherapy 14 (7): 929–935. doi:10.1517/14656566.2013.780030. PMID 23488774. 
  11. ^ Schöffski, P (June 2012). "Pazopanib in the treatment of soft tissue sarcoma". Expert Review of Anticancer Therapy 12 (6): 711–723. doi:10.1586/era.12.41. PMID 22716487. 
  12. ^ Pick, AM; Nystrom, KK (March 2012). "Pazopanib for the treatment of metastatic renal cell carcinoma". Clinical Therapeutics 34 (3): 511–520. doi:10.1016/j.clinthera.2012.01.014. PMID 22341567.